| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0088 | 0.9 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.9 |
| mRNA | avicin D | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.9 |